. Author manuscript; available in PMC: 2025 Feb 1.

Published in final edited form as: Transplant Cell Ther. 2023 Oct 21;30(2):171–186. doi: 10.1016/j.jtct.2023.10.013

TABLE 1.

Summary of key clinical trials of FDA-regulated cell therapy products against T cell neoplasms as registered on clinicaltrials.gov.

Trial Number	Sponsor	Target	Phase	Product	Disease	Status	Ref.^*
NCT04712864	Legend Biotech USA, Inc.	CD4	I	Autologous	R/R CD4+ PTCL R/R CTCL and MF	Terminated
NCT03829540	iCell Gene Therapeutics	CD4	I	Autologous	R/R T-cell leukemia, T-NHL	Recruiting
NCT03081910	Baylor College of Medicine	CD5	I	Autologous	R/R T-ALL, T-NHL	Recruiting	^92,94
NCT03690011	Baylor College of Medicine	CD7	I	Autologous	R/R T-ALL, T-NHL	Recruiting
NCT04984356	Wugen, Inc.	CD7	I/II	Allogeneic	R/R T-ALL, T-LBL	Recruiting	¹²⁸
NCT05377827	University of Washington	CD7	I	Allogenic	T-NHL, AML	Recruiting
NCT04083495	University of North Carolina – Chapel Hill	CD30	II	Autologous	R/R PTCL	Recruiting	¹²⁹
NCT02690545	University of North Carolina – Chapel Hill	CD30	I	Autologous	R/R HL, NHL	Recruiting	^105,130
NCT02663297	University of North Carolina – Chapel Hill	CD30	I	Autologous	HL, NHL in remission	Active, NR	¹³¹
NCT04526834	Tessa Therapeutics	CD30	I	Autologous	R/R PTCL, DLBCL, PMBCL	Active, NR
NCT02917083	Baylor College of Medicine	CD30	I	Autologous	R/R HL, NHL	Recruiting	¹⁰⁵
NCT01192464	Baylor College of Medicine	CD30	I	Autologous cytotoxic T lymphocytes	R/R HL, NHL	Active, NR
NCT04288726	Baylor College of Medicine	CD30	I	Allogeneic	R/R NK/T-cell lymphoma, HL	Recruiting	¹³²
NCT03049449	National Cancer Institute	CD30	I	Autologous	R/R NHL	Completed	¹³³
NCT03602157	University of North Carolina – Chapel Hill	CD30 + CCR4	I	Autologous	NHL	Recruiting	¹³⁴
NCT04136275	Massachusetts General Hospital	CD37	I	Autologous	R/R CD37+ hematological malignancy	Recruiting	¹³⁵
NCT04502446	CRISPR Therapeutics	CD70	I	Allogeneic	R/R T-NHL	Recruiting	¹¹³
NCT03590574	Autolus Limited	TRBC1	I/II	Autologous	R/R T-NHL	Recruiting	¹²²

PCTL = peripheral T-cell lymphoma; CTCL = cutaneous T cell lymphoma; MF = mycosis fungoides; T-ALL = T cell acute lymphoblastic leukemia; T-NHL = T cell Non-Hodgkin lymphoma; T-LBL = T cell lymphoblastic lymphoma; AML = acute myelogenous leukemia; DLBCL = diffuse large B cell lymphoma; PMBCL = primary mediastinal B cell lymphoma; HL = Hodgkin lymphoma; NHL = Non-Hodgkin lymphoma; R/R = Relapsed and/or refractory, TRBC1 = T-cell receptor p-chain constant region 1.

Ref. = Most recent reference is provided for reported and publicly distributed clinical trial results as of October 2023.